Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma
-
- Gerald P. Linette
- Siteman Cancer Center and Departments of Medicine and Pathology and Immunology, Washington University School of Medicine, St. Louis, MO;
-
- Edward A. Stadtmauer
- Abramson Cancer Center, Department of Medicine, and Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA;
-
- Marcela V. Maus
- Abramson Cancer Center, Department of Medicine, and Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA;
-
- Aaron P. Rapoport
- The Greenebaum Cancer Center, University of Maryland, Baltimore, MD;
-
- Bruce L. Levine
- Abramson Cancer Center, Department of Medicine, and Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA;
-
- Lyndsey Emery
- Abramson Cancer Center, Department of Medicine, and Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA;
-
- Leslie Litzky
- Abramson Cancer Center, Department of Medicine, and Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA;
-
- Adam Bagg
- Abramson Cancer Center, Department of Medicine, and Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA;
-
- Beatriz M. Carreno
- Siteman Cancer Center and Departments of Medicine and Pathology and Immunology, Washington University School of Medicine, St. Louis, MO;
-
- Patrick J. Cimino
- Siteman Cancer Center and Departments of Medicine and Pathology and Immunology, Washington University School of Medicine, St. Louis, MO;
-
- Gwendolyn K. Binder-Scholl
- Adaptimmune Ltd, Philadelphia and Abingdon, United Kingdom; and
-
- Dominic P. Smethurst
- Adaptimmune Ltd, Philadelphia and Abingdon, United Kingdom; and
-
- Andrew B. Gerry
- Adaptimmune Ltd, Philadelphia and Abingdon, United Kingdom; and
-
- Nick J. Pumphrey
- Adaptimmune Ltd, Philadelphia and Abingdon, United Kingdom; and
-
- Alan D. Bennett
- Adaptimmune Ltd, Philadelphia and Abingdon, United Kingdom; and
-
- Joanna E. Brewer
- Adaptimmune Ltd, Philadelphia and Abingdon, United Kingdom; and
-
- Joseph Dukes
- Immunocore Ltd, Abingdon, United Kingdom
-
- Jane Harper
- Immunocore Ltd, Abingdon, United Kingdom
-
- Helen K. Tayton-Martin
- Adaptimmune Ltd, Philadelphia and Abingdon, United Kingdom; and
-
- Bent K. Jakobsen
- Adaptimmune Ltd, Philadelphia and Abingdon, United Kingdom; and
-
- Namir J. Hassan
- Immunocore Ltd, Abingdon, United Kingdom
-
- Michael Kalos
- Abramson Cancer Center, Department of Medicine, and Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA;
-
- Carl H. June
- Abramson Cancer Center, Department of Medicine, and Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA;
書誌事項
- 公開日
- 2013-08-08
- DOI
-
- 10.1182/blood-2013-03-490565
- 公開者
- American Society of Hematology
この論文をさがす
説明
<jats:title>Key Points</jats:title> <jats:p>Engineered T-cell receptors can have redundant recognition of alternative protein motifs, resulting in severe cardiac toxicity. The use of induced pleuripotent stem cells (iPSCs) is a promising approach to identify potential off-target effects of engineered T cells.</jats:p>
収録刊行物
-
- Blood
-
Blood 122 (6), 863-871, 2013-08-08
American Society of Hematology